Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease

Future Cardiology

Volumn 2, Issue 1, 2006, Pages 85-91

  Ruff, Christian T ^a   Giugliano, Robert ^a   Morrow, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Anticoagulation; Coronary artery disease; NAPc2; Sunol cH36; Tissue factor; Tissue factor pathway inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NEW DRUG; PLACEBO; PROTEINASE ACTIVATED RECEPTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBOPLASTIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ADENOVIRUS; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTERY THROMBOSIS; BLEEDING DISORDER; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DOWNSTREAM PROCESSING; DRUG BINDING SITE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENZYME INHIBITION; HEART DISEASE; HEART INFARCTION; HUMAN; MOLECULAR MECHANICS; MUCOSAL BLEEDING; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; VIRAL GENE DELIVERY SYSTEM;

EID: 33646570225     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.1.85     Document Type: Review

References (33)

1. Toschi V, Gallo R, Lettino M et al.: Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95, 594-599 (1997).
2. Dahlback B: Blood coagulation. Lancet 355, 1627-1632 (2000).
3. Camerer E, Kolsto AB, Prydz H: Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb. Res. 81, 1-41 (1996).
4. Moreno PR, Bernardi VH, Lopez-Cuellar J et al.: Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 94, 3090-3097 (1996).
5. Mann KG: Biochemistry and physiology of blood coagulation. Thromb. Haemost. 82, 165-174 (1999).
6. Byzova TV, Plow EF: Networking in the hemostatic system. Integrin α2β3 binds prothrombin and influences its activation. J. Biol. Chem. 272, 27183-27188 (1997).
7. Misumi K, Ogawa H, Yasue H et al.: Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am. J. Cardiol. 81, 22-26 (1998).
8. Soejima H, Ogawa H, Yasue H et el.: Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 99, 2908-2913 (1999).
9. Ahamed J, Ruf W: Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J. Biol. Chem. 279, 23038-23044 (2004).
10. Zoldhelyi P, McNatt J, Shelat HS, Yamamoto Y, Chen ZQ, Willerson JT: Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 101, 289-295 (2000).
11. Harker LA, Hanson SR, Kelly AB: Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb. Haemost. 78, 736-741 (1997).
12. Glesen PL, Rauch U, Bohrmann B et al.: Blood-borne tissue factor: another view of thrombosis. Proc. Natl Acad. Sci. USA 96, 2311-2315 (1999).
13. Hutter R, Valdiviezo C, Sauter BV et al.: Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation 109, 2001-2008 (2004).
14. Sambola A, Osende J, Hathcock J et al.: Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107, 973-977 (2003).
15. Orfeo T, Butenas S, Brummel-Ziedins KE, Mann KG: The tissue factor requirement in blood coagulation. J. Biol. Chem. (2005). Published ahead of print 10.1074/jbc.M505506200
16. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM: Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 349, 769-771 (1997).
17. Kaikita K, Ogawa H, Yasue H et al.: Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler. Thromb. Vasc. Biol. 17, 2232-2237 (1997).
18. Soejima H, Ogawa H, Yasue H et al.: Effects of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction. Am. J. Cardiol. 78, 336-340 (1996).
19. Levi M, Ten Cate H: Disseminated intravascular coagulation. N. Engl. J. Med. 341, 586-592 (1999).
20. Rao LV, Rapaport SI: Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 69, 645-651 (1987).
21. Broze GJ Jr: The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin. Hematol. 29, 159-169 (1992).
22. Girard TJ, Warren LA, Novotny WF et al.: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338, 518-520 (1989).
23. Sandset PM, Sirnes PA, Abildgaard U: Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br. J. Haematol. 72, 391-396 (1989).
24. Haskel EJ, Torr SR, Day KC et al.: Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 84, 821-827 (1991).
25. Jang Y, Guzman LA, Lincoff AM et al.: Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 92, 3041-3050 (1995).
26. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB: Tissue factor pathway inhibitor reduces mortality from Escherichia coll septic shock. J. Clin. Invest. 91, 2850-2860 (1993).
27. Abraham E, Reinhart K, Opal S et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290, 238-247 (2003).
28. de Jonge E, Dekkers PE, Creasey AA et al.: Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 95, 1124-1129 (2000).
29. Duggan BM, Dyson HJ, Wright PE: Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2. Eur. J. Biochem. 265, 539-548 (1999).
30. Weijer S, Schoenmakers SH, Florquin S et al.: Inhibition of the tissue factor/Factor VIIa pathway does not Influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice. J. Infect. Dis. 189, 2308-2317 (2004).
31. Lee A, Agnelli G, Buller H et al.: Dose-response study of recombinant Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 104, 74-78 (2001).
32. Moons AH, Peters RJ, Bijsterveld NR et al.: Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/Factor VIIa complex, in patients undergoing elective coronary angioplasty. J. Am. Coll. Cardiol. 41, 2147-2153 (2003).
33. Morrow DA, Murphy SA, McCabe CH, Mackman N, Wong HC, Amman EM: Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur. Heart J. 26, 682-688 (2005).